Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising new agents in oncologic treatment

S Mani1, M J Ratain

  • 1Department of Medicine, University of Chicago, IL 60637-1470, USA.

Current Opinion in Oncology
|November 1, 1996
PubMed
Summary

Several novel cytotoxic anticancer agents, including new taxanes and thymidylate synthase inhibitors, are in clinical development. These rationally designed drugs show promise for various cancers and are entering phase II and III trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Hormonal stimulation reduces numbers and impairs function of human uterine natural killer cells during implantation.

Human reproduction (Oxford, England)·2023
Same author

Potential antiviral effects of pantethine against SARS-CoV-2.

Scientific reports·2023
Same author

Urinary Ascites and Transient Intestinal Obstruction in a Preterm Infant: An Interesting Case of Posterior Urethral Valve.

AJP reports·2019
Same author

<i>REPLY</i>.

AJNR. American journal of neuroradiology·2018
Same author

Brain Imaging in Cases with Positive Serology for Dengue with Neurologic Symptoms: A Clinicoradiologic Correlation.

AJNR. American journal of neuroradiology·2018

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Recent advancements have introduced novel anticancer agents into clinical practice.
  • These drugs exhibit diverse mechanisms, including direct cytotoxicity and anti-angiogenesis.
  • The review specifically examines cytotoxic drugs developed within the last five years.

Purpose of the Study:

  • To review cytotoxic anticancer agents in clinical development.
  • To highlight recently emerged drugs with novel therapeutic effects.
  • To discuss their current clinical trial status.

Main Methods:

  • Literature review of cytotoxic anticancer drugs in clinical development.
  • Focus on agents with novel mechanisms and those developed in the past five years.
  • Inclusion of drugs in phase II and III clinical trials.

Related Experiment Videos

Main Results:

  • Several novel cytotoxic agents are in clinical development, including docetaxel, irinotecan (CPT-11), raltitrexed (ZD 1694, Tomudex), gemcitabine, and oral 5-fluorouracil alternatives.
  • These drugs represent rationally designed therapies with unique mechanisms of action.
  • Many have advanced to phase II or III clinical trials.

Conclusions:

  • Novel cytotoxic anticancer drugs are increasingly finding clinical application.
  • Ongoing phase II and III trials will provide crucial data on their efficacy and safety.
  • These agents represent a significant advancement in cancer therapy.